Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- D. Boral Capital analyst Jason Kolbert initiated coverage on NeuroSense Therapeutics Ltd. NRSN with a Buy rating and announced a price target of $14. NeuroSense Therapeutics shares closed at $1.0438 on Friday. See how other analysts view this stock.
- Maxim Group analyst Jason McCarthy initiated coverage on ProMIS Neurosciences, Inc. PMN with a Buy rating and announced a price target of $3. ProMIS Neurosciences shares closed at $0.5020 on Friday. See how other analysts view this stock.
- Maxim Group initiated coverage on Primis Financial Corp. FRST with a Buy rating and announced a price target of $1. Primis Finl shares closed at $8.96 on Friday. See how other analysts view this stock.
Considering buying NRSN stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.